All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear from you! 📣

(You can also reach out to me on LinkedIn)

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

THE GOOD
Approvals & Labels

Antengene’s Xpovio (selinexor) gets China NMPA approval for 2nd indication
Small molecule, B-cell lymphoma, cancer - Read more

THE GOOD
Fundraises

Myricx Bio £90M ($114M) Series A
Antibody-drug conjugate - Read more

Circle Pharma $54M Series D
Macrocycle, solid tumor, cancer - Read more [Paywall]

Kvantify €10M ($10.8M) Seed raise
Quantum computing, drug development - Read more

Granza Bio $7M Seed raise
Drug delivery, cancer - Read more

THE GOOD
Investments

Lotte Biologics breaks ground on 4.6 trillion won ($3.33B) campus
CDMO, contract manufacturing - Read more 

THE GOOD
Mergers & Acquisitions

Genexine, EPD Biotherapeutics merger
mRNA, protein degrader, LNP, cancer - Read more

THE GOOD
Patient Access

First two patients treated with CSL Behring’s Hemgenix gene therapy
AAV gene therapy, Hemophilia B - Read more

THE GOOD
Research

Another win for GLP-1s, reduce risk of certain obesity-linked cancers in diabetic patients; study
GLP-1, diabetes, obesity, cancer - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

Genentech halts mAb combo lung cancer Ph2/3 on less than SKYSCRAPing efficacy
Monoclonal antibody body, lung cancer - Read more

THE BAD
Lawsuits

Boehringer Ingelheim’s attempted medicare price negotiation legal challenge is blocked in Connecticut court
Drug pricing, Medicare - Read more 

THE BAD
Partnerships

Servier, Pieris Pharmaceuticals partnership ends over safety concerns
Fusion protein, immuno-oncology, cancer - Read more

THE UGLY
Marketing

Novartis, Pfizer, Otsuka, Novo Nordisk have “brought discredit upon, and reduced confidence in, the pharmaceutical industry”
Drug advertising, ABPI Code of Practice - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.